Wall Street brokerages expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to announce earnings of $2.50 per share for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Regeneron Pharmaceuticals’ earnings. Regeneron Pharmaceuticals posted earnings per share of $1.45 during the same quarter last year, which would suggest a positive year-over-year growth rate of 72.4%. The firm is expected to issue its next earnings report before the market opens on Thursday, May 4th.
On average, analysts expect that Regeneron Pharmaceuticals will report full year earnings of $10.17 per share for the current fiscal year, with EPS estimates ranging from $9.84 to $10.50. For the next financial year, analysts anticipate that the firm will report earnings of $10.90 per share, with EPS estimates ranging from $10.78 to $11.02. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, February 9th. The biopharmaceutical company reported $3.04 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.01. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. The business earned $1.23 billion during the quarter, compared to analysts’ expectations of $1.30 billion. During the same quarter in the prior year, the firm earned $2.83 earnings per share. The business’s revenue was up 11.7% compared to the same quarter last year.
A number of equities analysts recently issued reports on REGN shares. Zacks Investment Research raised Regeneron Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 15th. Canaccord Genuity reissued a “hold” rating and set a $375.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, March 30th. Goldman Sachs Group Inc lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Thursday, February 16th. Oppenheimer Holdings Inc. started coverage on Regeneron Pharmaceuticals in a report on Thursday, March 16th. They set a “hold” rating on the stock. Finally, BMO Capital Markets reissued a “hold” rating and set a $412.00 price target (up previously from $408.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 28th. Thirteen investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $430.13.
In related news, Director Michael S. Brown sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, March 29th. The stock was sold at an average price of $400.00, for a total transaction of $400,000.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $400,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.40% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of REGN. Alpha Windward LLC increased its position in shares of Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares in the last quarter. Grandfield & Dodd LLC increased its position in shares of Regeneron Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 1,497 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 17 shares during the period. Waldron LP increased its position in shares of Regeneron Pharmaceuticals by 2.1% in the third quarter. Waldron LP now owns 856 shares of the biopharmaceutical company’s stock valued at $344,000 after buying an additional 18 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Regeneron Pharmaceuticals by 0.6% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,334 shares of the biopharmaceutical company’s stock valued at $1,591,000 after buying an additional 24 shares during the period. Finally, Douglass Winthrop Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 3.8% in the third quarter. Douglass Winthrop Advisors LLC now owns 675 shares of the biopharmaceutical company’s stock valued at $271,000 after buying an additional 25 shares during the period. Hedge funds and other institutional investors own 68.83% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Analysts Anticipate Regeneron Pharmaceuticals Inc (REGN) to Announce $2.50 Earnings Per Share” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://sportsperspectives.com/2017/05/20/analysts-anticipate-regeneron-pharmaceuticals-inc-regn-to-announce-2-50-earnings-per-share-updated-updated.html.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 5.97% during trading on Thursday, hitting $388.49. The company’s stock had a trading volume of 2,180,107 shares. The company has a 50-day moving average price of $378.33 and a 200-day moving average price of $374.50. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $452.96. The stock has a market cap of $40.97 billion, a PE ratio of 50.46 and a beta of 1.44.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.